pharmaand
As of the edition of 20 October 2026, pharmaand runs 5 drugs, 4 of them marketed; it is on route A at 5 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Stopped | 1 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Peginterferon alfa-2a | Ended 2014 (computed from the first US licence) | 0 |
| Panobinostat | Ends 2028 (patent) | 0 |
| Rucaparib | Ends 2031 (patent) | 5 |
| Darifenacin | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 3 targets.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where pharmaand needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 6 trials led
- Hormones: 5 trials led
- Pregnancy and women's health: 4 trials led